Cargando…

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paoluzzi, L., Cacavio, A., Ghesani, M., Karambelkar, A., Rapkiewicz, A., Weber, J., Rosen, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200964/ https://www.ncbi.nlm.nih.gov/pubmed/28042471 http://dx.doi.org/10.1186/s13569-016-0064-0

Ejemplares similares

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Extraskeletal myxoid chondrosarcoma with massive pulmonary metastases
por: Paoluzzi, Luca, et al.
Publicado: (2018)

Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review
por: Vieira, Aline Cristini, et al.
Publicado: (2020)

Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
por: Mizutani, Kosuke, et al.
Publicado: (2017)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
por: Mantripragada, Kalyan, et al.
Publicado: (2015)

A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report
por: Tokuhara, Katsuji, et al.
Publicado: (2017)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017)

Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
por: Obata, Shumpei, et al.
Publicado: (2019)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
por: Chen, Yaolin, et al.
Publicado: (2021)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
por: Zhou, Maggie, et al.
Publicado: (2021)

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
por: Paraghamian, Sarah E., et al.
Publicado: (2017)

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
por: Nakahara, Yoshiro, et al.
Publicado: (2018)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
por: Inoue, Hiroyuki, et al.
Publicado: (2016)

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
por: Narumi, Yoshitsugu, et al.
Publicado: (2018)

Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
por: Torrente-López, Anabel, et al.
Publicado: (2022)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy
por: Wosnitzer, Brian, et al.
Publicado: (2015)

Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
por: Shin, Jong, et al.
Publicado: (2021)

Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report
por: Tang, Xiao, et al.
Publicado: (2020)

Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series
por: Goodman, Rachel S, et al.
Publicado: (2023)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers
por: Tengesdal, Isak W., et al.
Publicado: (2022)

Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?
por: Miao, Ruoyu, et al.
Publicado: (2023)

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy
por: Fareed, Muhammad Mohsin, et al.
Publicado: (2019)

Vogt‐Koyanagi‐Harada disease‐like posterior uveitis in the course of nivolumab (anti‐PD‐1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma
por: Matsuo, Toshihiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3ulclhlnp0s2gb9oh5hpsqi2j8